Free Trial

Corvus Pharmaceuticals (CRVS) Insider Trading & Ownership

Corvus Pharmaceuticals logo
$4.70 -2.69 (-36.40%)
(As of 09:46 AM ET)

Corvus Pharmaceuticals (NASDAQ:CRVS) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
31.30%
Number Of
Insiders Buying
(Last 12 Months)
2
Amount Of
Insider Buying
(Last 12 Months)
$1.03 M
Number Of
Insiders Selling
(Last 12 Months)
0
Get CRVS Insider Trade Alerts

Want to know when executives and insiders are buying or selling Corvus Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

CRVS Insider Buying and Selling by Quarter

Corvus Pharmaceuticals Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/6/2024Richard A Md MillerCEOBuy577,634$1.73$999,306.82  
5/6/2024William Benton JonesInsiderBuy20,000$1.73$34,600.00  
(Data available from 1/1/2013 forward)

CRVS Insider Trading Activity - Frequently Asked Questions

The list of insiders at Corvus Pharmaceuticals includes Leiv Lea, Linda Grais, Richard A Md Miller, and William Benton Jones. Learn more on insiders at CRVS.

31.30% of Corvus Pharmaceuticals stock is owned by insiders. Learn more on CRVS's insider holdings.

The following insiders have purchased CRVS shares in the last 24 months: Linda Grais ($24,500.00), Richard A Md Miller ($999,306.82), and William Benton Jones ($50,400.00).

Insiders have purchased a total of 627,634 CRVS shares in the last 24 months for a total of $1,074,206.82 bought.

Corvus Pharmaceuticals Key Executives

  • Dr. Richard A. Miller M.D. (Age 73)
    Co-Founder, President, CEO & Chairman of the Board
    Compensation: $116.31k
  • Dr. Peter A. Thompson FACP (Age 64)
    M.D., Co-Founder & Independent Director
    Compensation: $47k
  • Mr. Leiv Lea (Age 70)
    Chief Financial Officer
    Compensation: $400.21k
  • Dr. William Benton Jones Ph.D. (Age 58)
    Senior Vice President of Pharmaceutical Development
    Compensation: $355.7k
  • Dr. James T. Rosenbaum M.D.
    Senior Vice President of Research
  • Mr. Jeffrey S. Arcara
    Chief Business Officer


This page (NASDAQ:CRVS) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners